Amikin, Arikayce liposomal(amikacin)
Arikayce (amikacin) is a small molecule pharmaceutical. Amikacin was first approved as Amikin on 1982-01-01. It is used to treat acinetobacter infections, bacterial infections, burns, central nervous system infections, and endocarditis amongst others in the USA. It has been approved in Europe to treat respiratory tract infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| musculoskeletal diseases | D009140 |
| respiratory tract diseases | D012140 |
| nervous system diseases | D009422 |
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
| skin and connective tissue diseases | D017437 |
| signs and symptoms pathological conditions | D013568 |
| wounds and injuries | D014947 |
Trade Name
FDA
EMA
Arikayce (generic drugs available since 1993-09-28, discontinued: Amikin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amikacin sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ARIKAYCE KIT | Insmed | N-207356 RX | 2018-09-28 | 1 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| amikacin sulfate | ANDA | 2023-04-07 |
| arikayce | New Drug Application | 2021-04-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| acinetobacter infections | EFO_1000792 | D000151 | — |
| bacterial infections | — | D001424 | A49 |
| burns | — | D002056 | T30.0 |
| central nervous system infections | EFO_1001456 | D002494 | A81 |
| endocarditis | EFO_0000465 | D004696 | I33 |
| escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
| infectious bone diseases | — | D001850 | — |
| infectious skin diseases | — | D012874 | — |
| intraabdominal infections | — | D059413 | — |
| klebsiella infections | EFO_1001353 | D007710 | — |
Show 9 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
AMIKACIN SULFATE, ARIKAYCE KIT, INSMED INC | |||
| 2030-09-28 | GAIN | ||
| 2025-09-28 | ODE-214 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Amikacin Sulfate, Arikayce Kit, Insmed Inc | |||
| 9895385 | 2035-05-15 | U-2417 | |
| 10251900 | 2035-05-15 | U-2414 | |
| 10751355 | 2035-05-15 | U-2414 | |
| 11446318 | 2035-05-15 | U-2414 | |
| 9566234 | 2034-01-18 | DP | U-2415 |
| 8226975 | 2028-08-15 | DP | |
| 8632804 | 2026-12-05 | U-2416 | |
| 8642075 | 2026-12-05 | DP | |
| 8679532 | 2026-12-05 | U-2415 | |
| 7718189 | 2025-06-06 | DP | U-2415 |
| 8802137 | 2024-04-08 | DP | U-2414 |
| 9827317 | 2024-04-08 | DP | U-2415 |
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06A: Antibiotics for topical use
— D06AX: Other antibiotics for topical use in atc
— D06AX12: Amikacin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01G: Aminoglycoside antibacterials
— J01GB: Other aminoglycosides in atc
— J01GB06: Amikacin
— J01R: Combinations of antibacterials
— J01RA: Combinations of antibacterials
— J01RA06: Cefepime and amikacin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA21: Amikacin
HCPCS
Code | Description |
|---|---|
| J0278 | Injection, amikacin sulfate, 100 mg |
Clinical
Clinical Trials
66 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sepsis | D018805 | A41.9 | — | — | 1 | 2 | 2 | 5 | |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 3 | — | 1 | 1 | 5 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 1 | — | 1 | 2 | 4 |
| Infections | D007239 | EFO_0000544 | — | — | — | 3 | — | 3 | |
| Bronchiectasis | D001987 | HP_0002110 | J47 | — | 1 | — | 2 | — | 3 |
| Bacterial infections | D001424 | A49 | — | — | — | 1 | 1 | 2 | |
| Febrile neutropenia | D064147 | — | — | — | 1 | 1 | 2 | ||
| Catheterization | D002404 | — | — | — | 1 | — | 1 | ||
| Meningitis | D008581 | EFO_0000584 | G03 | — | — | — | 1 | — | 1 |
| Bacterial meningitis | D016920 | EFO_1000831 | G00 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | 2 | 2 | — | 5 | 9 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 3 | 1 | — | — | 4 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | 1 | 2 | — | 2 | 4 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | 1 | — | 1 | 3 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | 1 | — | 1 | 2 |
| Nontuberculous mycobacterium infections | D009165 | EFO_0007461 | A31.9 | — | 1 | 1 | — | — | 2 |
| Pseudomonas infections | D011552 | EFO_0001076 | — | — | 1 | — | — | 1 | |
| Disease progression | D018450 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | 2 | 3 |
| Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | — | 1 | — | — | — | 1 | |
| Urinary bladder neoplasms | D001749 | C67 | — | 1 | — | — | — | 1 | |
| Urologic surgical procedures | D013520 | — | 1 | — | — | — | 1 | ||
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | — | — | — | 1 | 4 | ||
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | — | — | — | 1 | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Septic shock | D012772 | A48.3 | — | — | — | — | 3 | 3 | |
| Neonatal sepsis | D000071074 | HP_0040187 | — | — | — | — | 2 | 2 | |
| Chronic bronchitis | D029481 | J42 | — | — | — | — | 1 | 1 | |
| Cerebral hemorrhage | D002543 | — | — | — | — | 1 | 1 | ||
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | — | — | 1 | 1 |
| Drug monitoring | D016903 | — | — | — | — | 1 | 1 | ||
| Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | — | — | — | — | 1 | 1 |
| Pharmacokinetics | D010599 | — | — | — | — | 1 | 1 | ||
| Critical illness | D016638 | — | — | — | — | 1 | 1 | ||
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | AMIKACIN |
| INN | amikacin |
| Description | Amikacin is an amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group. It has a role as an antimicrobial agent, an antibacterial drug and a nephrotoxin. It is an alpha-D-glucoside, an aminoglycoside, a carboxamide and an amino cyclitol glycoside. It is functionally related to a kanamycin A. It is a conjugate base of an amikacin(4+). |
| Classification | Small molecule |
| Drug class | antibiotics obtained from Streptomyces kanamyceticus (related to kanamycin) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 37517-28-5 |
| RxCUI | 641 |
| ChEMBL ID | CHEMBL177 |
| ChEBI ID | 2637 |
| PubChem CID | 37768 |
| DrugBank | DB00479 |
| UNII ID | 84319SGC3C (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 33,213 documents
View more details
Safety
Black-box Warning
Black-box warning for: Amikacin sulfate, Arikayce
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,044 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more